SAN DIEGO, Dec. 13 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA),
a company focused on commercializing technologies and products for
accelerating drug discovery and development, today announced that Tibotec
Group N.V., an emerging pharmaceutical company headquartered in Mechelen,
Belgium, has licensed Trega's iDEA(TM) Predictive ADME Simulation System for
absorption. Tibotec will utilize the iDEA(TM) absorption module in its drug
discovery activities, which are currently focused in the area of HIV and AIDS.
Tibotec was granted a multi-year site license to the iDEA(TM) absorption
module and has an option to license the iDEA(TM) metabolism module which is
scheduled for release at the end of this year. Financial terms were not
disclosed.
"We are very excited about gaining access to Trega's iDEA(TM) Predictive
ADME Simulation System, because we believe that in silico technologies will
assist our scientists in accelerating the drug discovery and development
process," said Tibotec chief executive officer Dr. Rudi Pauwels.
"Our licensing agreement with Tibotec reflects the expanding market for
our iDEA(TM) Predictive ADME Simulation System among smaller progressive
pharmaceutical and biotechnology companies. These modules have been designed
to accelerate and refine current drug discovery efforts and can offer improved
timelines to a wide range of pharmaceutical and biotechnology companies," said
Michael G. Grey, president and chief executive officer. "We view the
expansion of the market for our products as an indication of the success our
initial licensees have had with our products which we believe can be
duplicated across the biopharmaceutical industry."
The iDEA(TM) Predictive ADME (absorption, distribution, metabolism,
excretion) Simulation System for absorption is an efficient, validated and
highly predictive in silico solution developed in conjunction with five
prominent pharmaceutical companies. The absorption module was constructed to
simulate the physiological process of drug absorption, and incorporates human
physiological parameters. The model is trained with a proprietary database of
in vitro and human in vivo pharmacokinetic data for selected drugs and drug
candidates, including many that failed in the development process. This
training set of compounds is unique in that it represents a very diverse set
of drug properties. Trega plans to complete a metabolism module at the end of
this year and subsequently develop additional modules that will enable the
complete prediction of bioavailability.
Tibotec is an emerging pharmaceutical company that has established a
powerful and effective platform for rapidly discovering and developing
superior drugs for unmet medical needs. The Company is initially focusing its
efforts on HIV and AIDS. Tibotec has created this platform by combining
leading edge, proprietary drug discovery tools with a multidisciplinary and
integrated approach to the drug discovery and development process. Tibotec is
developing novel anti-HIV drugs that address the serious problems of drug
resistance, compliance and side effects. Tibotec was founded in 1994 and has
over 150 staff worldwide. The Company has three sites: Mechelen, Belgium;
Rockville, Maryland, USA; and Dublin, Ireland. For more information on
Tibotec please see the website at http://www.tibotec.com.
Trega Biosciences, Inc. (Nasdaq: TRGA) is a premier provider of products
that accelerate and improve drug discovery through its iDiscovery(TM)
technologies linking biology and chemistry with information technologies.
Trega's iDEA(TM) family of information-based models simulate, in silico, how
drug candidates will be processed in the body, thereby enabling selection of
those with optimal characteristics for clinical development. Together with
its iDEA(TM) products, Trega's ChemFolio(R) libraries of information-enhanced
small molecules are designed to facilitate the identification and optimization
of drug candidates. For additional information on Trega, please visit our Web
site at http://www.trega.com.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including whether this transaction will be
successful, any additional licenses, alliances or other transactions will be
agreed to, formed or expanded, whether any such transactions will be
successful, the impact of competitive products and pricing, and other risks
detailed from time to time in Trega's Securities and Exchange Commission
filings. These forward-looking statements represent Trega's judgment as of
the date of this release. Trega disclaims, however, any intent or obligation
to update these forward-looking statements.
SOURCE Trega Biosciences, Inc.
 back to top
Related links:
http://www.trega.com
Company News On-Call:
http://www.prnewswire.com/comp/374050.html or fax,
800-758-5804, ext. 374050
CONTACT:
Gerard A. Wills, Vice President, Finance &
CFO, 858-410-6695, or Cynthia Reindal, Corp. Communications &
Investor Relations, 858-410-6601, both of Trega Biosciences, Inc.
|
